|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2011-8-12
|
|
pubmed:abstractText |
To present an updated survival analysis of an open-label, parallel-group, phase IIB trial of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB or IV non-small-cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1432-1335
|
|
pubmed:author |
pubmed-author:BeierFrankF,
pubmed-author:ButtsCharlesC,
pubmed-author:CormierYvonY,
pubmed-author:EllisPeter MPM,
pubmed-author:FalkMartinM,
pubmed-author:GossGlenwoodG,
pubmed-author:MaksymiukAndrewA,
pubmed-author:MarshallErnieE,
pubmed-author:MurrayNevinN,
pubmed-author:PriceAllanA,
pubmed-author:SawhneyRavinderR,
pubmed-author:SoulièresDenisD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
137
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1337-42
|
|
pubmed:meshHeading |
pubmed-meshheading:21744082-Cancer Vaccines,
pubmed-meshheading:21744082-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:21744082-Female,
pubmed-meshheading:21744082-Humans,
pubmed-meshheading:21744082-Immunotherapy,
pubmed-meshheading:21744082-Liposomes,
pubmed-meshheading:21744082-Lung Neoplasms,
pubmed-meshheading:21744082-Male,
pubmed-meshheading:21744082-Membrane Glycoproteins,
pubmed-meshheading:21744082-Middle Aged,
pubmed-meshheading:21744082-Neoplasm Staging,
pubmed-meshheading:21744082-Survival Analysis,
pubmed-meshheading:21744082-Survival Rate
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
|
|
pubmed:affiliation |
Cross Cancer Institute, 11560 University Avenue, Edmonton, AB, T6G 1Z2, Canada. charles.butts@albertahealthservices.ca
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
